1.
Expert Opin Pharmacother
; 5(5): 1175-86, 2004 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15155116
RESUMO
The recent development of inhibitors of TNF-alpha has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel) since it entered the market 5 years ago.
Assuntos
Imunoglobulina G/farmacologia , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Etanercepte , Humanos , Imunoglobulina G/química , Imunoglobulina G/uso terapêutico , Receptores do Fator de Necrose Tumoral/química , Receptores do Fator de Necrose Tumoral/uso terapêutico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/farmacologia , Fator de Necrose Tumoral alfa/uso terapêutico
2.
Am J Med
; 116(9): 640-1, 2004 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15093762
3.
Arthritis Rheum
; 55(2): 333-7, 2006 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16583385